創新醫療(002173.SZ):前三季度預虧3200萬元-3800萬元
格隆匯10月14日丨創新醫療(002173.SZ)披露2021年前三季度業績預吿,預計2021年1-9月實現歸屬於上市公司股東的淨利潤為虧損3200萬元-3800萬元,上年同期為虧損4946.38萬元;預計2021年7-9月實現歸屬於上市公司股東的淨利潤為虧損1100萬元-1550萬元,上年同期為盈利399.01萬元。
2021年1-9月,公司下屬醫院經營活動受疫情影響程度與上年同期相比有所減緩,營業收入實現了小幅恢復性增長。公司報吿期內收到了陳夏英支付的全部珍珠資產股權轉讓尾款,公司針對此債權計提的壞賬準備745.93萬元全部轉回,同時公司收到了陳夏英支付的珍珠資產股權轉讓款項利息705.74萬元。
此外,報吿期公司使用部分募集資金進行現金管理購買理財產品,理財收益與上年同期相比增加較多。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.